Glaukos Corporation
iLink - Model KXL - Corneal Cross-Linking Procedure System
iLink is the first and only FDA-approved corneal cross-linking procedure that slows or halts the progression of keratoconus and helps preserve vision. Watch this video for unique patient and doctor perspectives about progressive keratoconus and learn how the condition is treated with iLink™ corneal cross-linking.
Most popular related searches
ophthalmology solution
cornea
drug manufacturer
cornea transplant
patient positioning
keratoconus
ophthalmology
disease diagnosis
irradiation system
cornea disease
Left untreated, 1 in 5 patients with progressive keratoconus may require a corneal transplant. As this disease is typically diagnosed in teens or early twenties, more than half of these patients could need multiple transplants within 20 years. 1,2
The KXL System
- UVA irradiation: 30 minutes at 3 mW/cm²
- Laser alignment for patient positioning
- Wireless control for beam alignment in the X, Y, and Z axes
- Fully integrated stable delivery platform
- Touchscreen operation
- Self-calibration of UVA irradiation intensity
Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution)
- Only FDA-approved bioactivated riboflavin ophthalmic solutions
- Manufactured using validated processes in a state-of-the-art drug manufacturing facility
- GMP-certified material
- Packaged and controlled under GMP standards